These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18294324)

  • 1. Gap in publication of comparative information on new medicines.
    van Luijn JC; Stolk P; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2008 May; 65(5):716-22. PubMed ID: 18294324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of comparator in active control trials of new drugs.
    van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
    Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with failure to publish large randomized trials presented at an oncology meeting.
    Krzyzanowska MK; Pintilie M; Tannock IF
    JAMA; 2003 Jul; 290(4):495-501. PubMed ID: 12876092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?
    Volodina A; Shah-Rohlfs R; Jahn A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1056-1066. PubMed ID: 36189466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An e-mail survey identified unpublished studies for systematic reviews.
    Reveiz L; Cardona AF; Ospina EG; de Agular S
    J Clin Epidemiol; 2006 Jul; 59(7):755-8. PubMed ID: 16765280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for obtaining unpublished drug trial data: a qualitative interview study.
    Wolfe N; Gøtzsche PC; Bero L
    Syst Rev; 2013 May; 2():31. PubMed ID: 23680054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public information on shortages in the EU/EEA: improvements made between 2018 and 2020.
    Abed I; Garcia Burgos J; Knudsen Y
    Eur J Hosp Pharm; 2024 Jun; 31(4):344-347. PubMed ID: 36754622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the usefulness of Internet searches to identify unpublished clinical trials for systematic reviews.
    Eysenbach G; Tuische J; Diepgen TL
    Med Inform Internet Med; 2001; 26(3):203-18. PubMed ID: 11706930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
    Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
    PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.